Noemí Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, comments on the challenges associated with developing a standardized technique for detecting measurable residual disease (MRD)-status in patients with myeloma. These include reproducibility, ease of use and interpretation, and cost. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.